Lifeloc Q3 Loss Narrows 68% to $85K; SpinDetect Launch Slips to Q4 2027
LCTC has more than doubled off its 52-week low of $1.75 on light trading volume (0.1× avg).
Summary
Lifeloc's Q3 loss narrowed to $84,931 on 12% higher revenue, but the company delayed its SpinDetect commercial launch from Q1 2027 to Q4 2027 and is leaning on a $500,000 related-party loan from its CFO/Chairman.
Key Events · Earnings and Guidance · LCTC
-
Q3 Loss Narrows on Higher Sales
Net loss was $84,931 versus $263,439 a year ago; revenue rose 12% to $2,521,874 and product gross margin improved to 43% from 40%.
-
SpinDetect Launch Delayed to Q4 2027
Limited commercial launch of the delta-9-THC oral-fluid analyzer slipped from the previously expected Q1 2027; engineering resources are being redirected to core breathalyzer upgrades to fund the program.
-
Insider Loan Funds the Balance Sheet
A $500,000 term loan from CFO and Chairman Vern D. Kornelsen, entered May 1, 2026, now carries a 10.75% rate after a prime-rate adjustment and is secured by substantially all company assets, subordinate to UMB.
-
Cash Position and Runway
Cash and equivalents were $930,539 at September 30, 2026; nine-month operating cash use was just $14,618, and management states cash resources fund operations for the next twelve months.
Analysis · LCTC · Industrial Applications And Services
The quarter itself improved: revenue rose 12% to $2.52M and the net loss shrank to $84,931 from $263,439, helped by a 43% product gross margin versus 40% a year ago. The bigger news is the timeline. Lifeloc pushed the limited commercial launch of its SpinDetect drug-detection platform from Q1 2027 to Q4 2027, and it is redirecting engineering resources back to the core breathalyzer line to generate the revenue needed to fund that work. With $930,539 of cash and a nine-month operating cash burn of only $14,618, the company says it has twelve months of runway, but the $500,000 related-party loan from its CFO and Chairman — now at 10.75% and secured by substantially all assets — means the balance sheet leans on insider financing while the growth product slips another three quarters.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LCTC was trading at $3.50 on OTC in the Industrial Applications And Services sector, with a market capitalization of approximately $9.6M. The 52-week trading range was $1.75 to $5.58. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.